Erratum: Optimal dosing of intravenous unfractionated heparin bolus in transient ischemic attack or stroke (Clinical and Applied Thrombosis/Hemostasis (2008) 16:2 (126-131) DOI: 10.1177/1076029608329579);Optimal dosing of intravenous unfractionated heparin bolus in transient ischemic attack or stroke

Clinical and Applied Thrombosis/Hemostasis

Volumn 16, Issue 2, 2010, Pages 126-131

  Kang, Kyusik ^a,c   Kim, Dong Wook ^b   Park, Hee Kwon ^c   Yoon, Byung Woo ^c  

^a Gyeongsang National University   (South Korea)

^b Konkuk University Hospital   (South Korea)

^c Seoul National University Hospital   (South Korea)

Author keywords

Anticoagulation; Bolus; Stroke; Transient ischemic attack; Unfractionated heparin

Indexed keywords

HEPARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; HEPARINIZATION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; TRANSIENT ISCHEMIC ATTACK;

EID: 77949880866     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029610373420     Document Type: Erratum

References (19)

1. Hirsh J., Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 ; 126: 188S - 203S.
2. Caplan LR Resolved: heparin may be useful in selected patients with brain ischemia. Stroke. 2003 ; 34: 230-231.
3. Adams HP Jr, del Zoppo G., Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007 ; 38: 1655-1711.
4. Chamorro A., Busse O., Obach V., et al. The rapid anticoagulation prevents ischemic damage study in acute stroke- final results from the writing committee. Cerebrovasc Dis. 2005 ; 19: 402-404.
5. Duke RJ, Bloch RF, Turpie AG, Trebilcock R., Bayer N. Intravenous heparin for the prevention of stroke progression in acute partial stable stroke. Ann Intern Med. 1986 ; 105: 825-828.
6. Schmidt WP, Heuschmann P., Taeger D., Henningsen H., Buecker-Nott HJ, Berger K. Determinants of IV heparin treatment in patients with ischemic stroke. Neurology. 2004 ; 63: 2407-2409.
7. Al-Sadat A., Sunbulli M., Chaturvedi S. Use of intravenous heparin by North American neurologists: do the data matter? Stroke. 2002 ; 33: 1574-1577.
8. Kang K., Yoon BW Symptomatic intracerebral hematomas in posterior circulation stroke patients anticoagulated with heparin. J Thromb Thrombolysis. 2006 ; 21: 249-255.
9. Camerlingo M., Salvi P., Belloni G., Gamba T., Cesana BM, Mamoli A. Intravenous heparin started within the first 3 hours after onset of symptoms as a treatment for acute nonlacunar hemispheric cerebral infarctions. Stroke. 2005 ; 36: 2415-2420.
10. Chamorro A., Vila N., Ascaso C., Blanc R. Heparin in acute stroke with atrial fibrillation: clinical relevance of very early treatment. Arch Neurol. 1999 ; 56: 1098-1102.
11. Cerebral Embolism Study Group. Cardioembolic stroke, early anticoagulation, and brain hemorrhage. Cerebral Embolism Study Group. Arch Intern Med. 1987 ; 147: 636-640.
12. Hochman JS, Wali AU, Gavrila D., et al. A new regimen for heparin use in acute coronary syndromes. Am Heart J. 1999 ; 138: 313-318.
13. Raschke RA, Reilly BM, Guidry JR, Srinivas S. The weight-based heparin dosing nomogram compared with a ĝ€ĝ€standard care nomogram. A randomized controlled trial. Ann Intern Med. 1993 ; 119: 874-881.
14. Toth C., Voll C. Validation of a weight-based nomogram for the use of intravenous heparin in transient ischemic attack or stroke. Stroke. 2002 ; 33: 670-674.
15. Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: a randomized trial. Cerebral Embolism Study Group. Stroke. 1983 ; 14: 668-676.
16. Berge E., Abdelnoor M., Nakstad PH, Sandset PM Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet. 2000 ; 355: 1205-1210.
17. Stroke Prevention in Atrial Fibrilllation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996 ; 348: 633-638.
18. Hylek EM, Go AS, Chang Y., et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003 ; 349: 1019-1026.
19. Cervera A., Justicia C., Reverter JC, Planas AM, Chamorro A. Steady plasma concentration of unfractionated heparin reduces infarct volume and prevents inflammatory damage after transient focal cerebral ischemia in the rat. J Neurosci Res. 2004 ; 77: 565-572.